Sun Pharmaceutical Industries Ltd has received USFDA approval for the Abbreviated New Drug Application (ANDA) to market generic Paraplatin Æ, carboplatin injection, the company informed the Bombay Stock Exchange.
These generic versions of carboplatin 10mg/ml injections packed in 5 ml, 15ml and 45 ml single use vials are bioequivalent to Paraplatin Æ injections distributed by Bristol Myers Squibb Oncology/Virology.
Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma.
These strengths of ParaplatinÆ Injections have annual sales of approximately $45 million in the US.
Paraplatin Æ is a registered trademark of Bristol Myers Squibb Company.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app